Biopharmaceutical Company Rebranded as Stablecoin Development Corporation

The corporate pivot playbook that Strategy wrote for Bitcoin is being applied to the stablecoin economy. A pharmaceutical company with under $10 million in annual revenue just became one of the largest holders of a stablecoin governance token.

The Pivot

NovaBay Pharmaceuticals, listed on NYSE American under the ticker NBY, announced a complete exit from its biopharmaceutical business and a full pivot into the digital asset space, rebranding as Stablecoin Development Corporation with the ticker SDEV effective April 3, 2026.

According to report by Coindesk, the company generated less than $10 million in revenue from its traditional eyecare business last year. It now oversees a SKY token position valued at approximately $144 million to $147 million, representing a balance sheet transformation of a scale rarely seen outside the Strategy model.

The SKY Position

As of March 16, 2026, Stablecoin Development Corporation holds approximately 2.06 billion SKY tokens, representing 8.78% of the total supply of Sky protocol’s governance token. The position was built through two separate channels. The January 2026 private placement provided 943.6 million SKY tokens as part of the financing structure. A subsequent open market accumulation added 1.09 billion SKY purchased at an average price of $0.065 per token. The company has already earned approximately 26.6 million SKY tokens in cumulative staking rewards on top of that base position, generating yield on its holdings before the rebrand is even complete.

The Financing Behind the Pivot

The strategic shift followed a $134 million private placement in January 2026 with a specific set of institutional participants: Tether Investments, Framework Ventures, R01 Fund LP, and the Sky Frontier Foundation. The involvement of Tether Investments is the most structurally significant detail in the investor lineup. Tether, the issuer of USDT and one of the most profitable entities in crypto, taking a position in a company pivoting to focus on the stablecoin economy through Sky protocol signals institutional conviction in the thesis beyond what a purely financial investor would represent.

To manage market stability, the warrants from the private placement are subject to a 9.9-month weighted-average delay before they can be fully exercised and sold, preventing immediate dilution from the financing participants and giving the company time to establish its operating model before the full warrant overhang becomes liquid.

What the Operating Model Looks Like

The company’s stated aim is to become a premier public vehicle for accessing cash flows from the stablecoin economy, specifically through the yield-bearing USDS stablecoin issued by the Sky protocol. That framing positions SDEV not as a speculative token holder but as a structured exposure vehicle for investors who want access to stablecoin yield generation through a publicly listed equity rather than through direct on-chain participation.

The Sky protocol, formerly MakerDAO, issues USDS as its dollar-pegged stablecoin and distributes yield to governance participants through the SKY token staking mechanism. Holding 8.78% of SKY’s total supply gives SDEV a meaningful governance position and a proportionally significant share of the protocol’s yield distribution. The 26.6 million SKY tokens already earned through staking represent the early operational output of that model before the company has completed its rebrand.

The Broader Context

The pivot arrives in the same week that USDC’s $4.5 billion year-to-date supply growth was covered in earlier reporting, the CLARITY Act’s stablecoin yield compromise advanced in Congress, and the CFTC confirmed digital assets as legitimate derivatives collateral. Each of those developments strengthens the investment thesis that stablecoin infrastructure is becoming institutional-grade financial infrastructure rather than a crypto-native niche. A publicly listed company restructuring its entire balance sheet around that thesis, with Tether as a co-investor, is a data point about where institutional conviction in the stablecoin economy currently sits.

The post Biopharmaceutical Company Rebranded as Stablecoin Development Corporation  appeared first on ETHNews.